UNITED ARAB EMIRATES · UAE PARTNERSHIP

Partnership in theUnited Arab Emirates.

For UAE distributors, pharmacy groups, regional trading houses and clinic networks: Continuum Innovative's portfolio has a longer history in this market than almost anything else on the shelf. The platform's brands were carried across UAE pharmacy retail through Boots Middle East, Aster Pharmacy, Life Pharmacy and Bin Sina Pharmacy.

The UAE is also the natural regional hub — many partners begin here and expand across the remaining GCC markets from a Dubai or Abu Dhabi base.

25+

YEARS OF UAE-CENTRED PRESENCE

PHARMACY NETWORKS PREVIOUSLY SERVED

PATENT-PENDING IP PROGRAMS

BRANDS AVAILABLE FOR THE UAE

WHY THE UAE IS THE REGIONAL HUB

Distribution reach beyond one market.

A UAE partner rarely thinks in one market. Dubai and Abu Dhabi based distributors typically service the wider Gulf, and often East Africa and parts of South Asia as well. That makes the UAE the most efficient place to restart a regional category position.

It is also the market where this portfolio's history is most visible. HairGenesis® and TrichoCyte™ were carried in UAE pharmacy retail for more than two decades. Pharmacist familiarity, consumer recognition and category credibility already exist here in a way they do not for a genuinely new entrant.

Distribution

UAE-specific or UAE-plus-GCC distribution rights for HairGenesis® and TrichoCyte™.

Licensing

Brand or private-label licensing for groups with their own consumer brand equity.

Clinic and aesthetic channel

Physician-dispensed and clinic-protocol supply alongside retail distribution.

Regional expansion

A UAE base from which Qatar, Kuwait, Bahrain, Oman and Saudi Arabia can be added by agreement.

WHAT MAKES THIS DEFENSIBLE

Mechanism, delivery, evidence, IP.

The category is crowded with products whose only differentiation is packaging. This portfolio differentiates on four things that a buyer can actually verify: a published mechanism, a delivery technology, peer-reviewed clinical and mechanistic evidence, and a patent-pending IP position.

TrichoCyte™ pairs botanical 5α-reductase inhibitors and anti-inflammatory phytochemicals with a β-cyclodextrin inclusion complex — the delivery vector, not the active alone, is the point. Six proprietary programs are the subject of provisional patent applications, which establish priority; they are not issued patents and we do not present them as such.

TrichoCyte™ mechanism and delivery.
Peer-reviewed publication record.
Six patent-pending programs.
Commercial record — 25 countries, $100M+ lifetime revenue.

COMMON QUESTIONS FROM UAE PARTNERS

Answered directly.

Can a UAE partner hold rights for other GCC markets?

Yes, multi-market arrangements are possible where the partner genuinely services those markets. Rights are granted against demonstrated reach, not aspiration.

Who handles UAE registration?

The partner. Continuum is not a UAE registration agent or regulatory consultancy and holds no UAE approvals of its own; we supply the scientific, technical, formulation and documentation materials that support the partner's filing.

Is the previous retail relationship transferable?

No relationship is transferred automatically. The relevance of the history is category credibility and buyer familiarity — the new partner builds its own commercial relationships.

What does the evaluation process look like?

See the due-diligence package. The open tier is available immediately, without confidentiality.

Partnership pathwaysAll available relationship structures.GCC distribution opportunitiesTerritories, channels and exclusivity.UAE — market pageOur existing UAE market documentation.Technology licensingBrand and private-label structures.GCC market entry supportThe support we provide our partners.الشراكات التجاريةThe Arabic partnership page.

NEXT STEP

Tell us what you already distribute in the UAE.

Channel, current portfolio, and the markets you service from here. We will respond with the scientific and commercial package.

OPEN A UAE DISCUSSION